Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
How do you approach management of recurrent idiopathic pleuropericarditis?
What would be the minimum duration of IL-1 therapy you would recommend for chronic pericarditis?
In patients with rheumatologic disease, which specific conditions are most strongly associated with mitral valve abnormalities (ex. Libman–Sacks endocarditis, valvulitis, or mitral regurgitation), and how does this influence your approach to screening, monitoring, or treatment?
How do you approach choosing between subcutaneous and IV actemra for RA?
How do you counsel patients with postural orthostatic tachycardia syndrome (POTS) regarding safe and effective exercise regimens?
How do you manage oral ulcers as a side effect from leflunomide?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
How do you approach the use of immunosuppressive therapy in patients with rheumatoid arthritis and underlying immunodeficiency, such as IgA deficiency?
What is a reasonable stepwise approach to diagnostic imaging when there is ongoing concern for cardiac amyloidosis?
